激素受体阳性-话题@MedSci

#激素受体阳性#

54篇内容 | 2681人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1980862, encodeId=1333198086214, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=让激素受体阳性乳腺癌患者的选择不再困难, objectType=article, longId=178554, objectId=abd51e85543b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abd51e85543b, replyNumber=0, likeNumber=0, createdTime=2019-09-06, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abd51e85543b, moduleTitle=让激素受体阳性乳腺癌患者的选择不再困难, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abd51e85543b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980867, encodeId=3ce8198086eb9, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Lancet Oncol：帕博西尼联合内分泌疗法治疗激素受体阳性、HER-2阴性的转移性乳腺癌, objectType=article, longId=182128, objectId=7074182128d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7074182128d0, replyNumber=0, likeNumber=94, createdTime=2020-05-29, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7074182128d0, moduleTitle=Lancet Oncol：帕博西尼联合内分泌疗法治疗激素受体阳性、HER-2阴性的转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7074182128d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980859, encodeId=90f2198085993, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Lancet Oncol：Tucidinostat联合依西美坦治疗激素受体阳性晚期乳腺癌, objectType=article, longId=165129, objectId=96ad1651296c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96ad1651296c, replyNumber=0, likeNumber=85, createdTime=2020-03-01, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96ad1651296c, moduleTitle=Lancet Oncol：Tucidinostat联合依西美坦治疗激素受体阳性晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96ad1651296c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980858, encodeId=ef0c1980858b1, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=王涛教授：激素受体阳性晚期乳腺癌一线优先推荐CDK4/6抑制剂联合内分泌治疗, objectType=article, longId=164383, objectId=f363164383a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f363164383a2, replyNumber=0, likeNumber=74, createdTime=2019-05-25, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f363164383a2, moduleTitle=王涛教授：激素受体阳性晚期乳腺癌一线优先推荐CDK4/6抑制剂联合内分泌治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f363164383a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980865, encodeId=b7de19808652f, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=2019 ESMO|内分泌治疗是激素受体阳性乳腺癌重要的治疗手段，Abemaciclib显著延长HR+/HER2-mBC患者PFS, objectType=article, longId=181298, objectId=eae9181298b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eae9181298b0, replyNumber=0, likeNumber=80, createdTime=2020-04-28, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eae9181298b0, moduleTitle=2019 ESMO|内分泌治疗是激素受体阳性乳腺癌重要的治疗手段，Abemaciclib显著延长HR+/HER2-mBC患者PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eae9181298b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980866, encodeId=23ec19808662a, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=绝经前激素受体阳性乳腺癌内分泌治疗选择卵巢功能抑制治疗获益评估, objectType=article, longId=181876, objectId=edeb1818e640, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edeb1818e640, replyNumber=0, likeNumber=62, createdTime=2020-08-07, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edeb1818e640, moduleTitle=绝经前激素受体阳性乳腺癌内分泌治疗选择卵巢功能抑制治疗获益评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edeb1818e640)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980851, encodeId=39791980851dd, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=PLOS ONE：雄激素受体阳性的三阴乳腺癌：临床病理，预后和预测特征, objectType=article, longId=140463, objectId=744b14046356, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=744b14046356, replyNumber=0, likeNumber=73, createdTime=2019-04-14, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=744b14046356, moduleTitle=PLOS ONE：雄激素受体阳性的三阴乳腺癌：临床病理，预后和预测特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=744b14046356)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980857, encodeId=6c6e198085ead, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=JAMA Oncol：激素受体阳性男性乳腺癌的辅助内分泌治疗应用现状及疗效观察, objectType=article, longId=157429, objectId=ee1f15e4296a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee1f15e4296a, replyNumber=0, likeNumber=89, createdTime=2019-05-11, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee1f15e4296a, moduleTitle=JAMA Oncol：激素受体阳性男性乳腺癌的辅助内分泌治疗应用现状及疗效观察, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee1f15e4296a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980852, encodeId=b192198085202, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=2018 AIOM建议：绝经前激素受体阳性的早期乳腺癌患者辅助内分泌治疗, objectType=article, longId=141220, objectId=4c3c141220a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c3c141220a0, replyNumber=0, likeNumber=53, createdTime=2019-04-14, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c3c141220a0, moduleTitle=2018 AIOM建议：绝经前激素受体阳性的早期乳腺癌患者辅助内分泌治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c3c141220a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980856, encodeId=e40319808569d, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=J Natl Cancer Inst：塞来昔布联用阿司匹林是绝经后激素受体阳性乳腺癌患者的福音？, objectType=article, longId=151815, objectId=b9ac151815da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9ac151815da, replyNumber=0, likeNumber=82, createdTime=2019-08-19, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9ac151815da, moduleTitle=J Natl Cancer Inst：塞来昔布联用阿司匹林是绝经后激素受体阳性乳腺癌患者的福音？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9ac151815da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980853, encodeId=46a21980853f4, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=CLIN CANCER RES：Pembrolizumab治疗雌激素受体阳性/HER2阴性晚期乳腺癌, objectType=article, longId=142003, objectId=8c6f142003d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c6f142003d6, replyNumber=0, likeNumber=73, createdTime=2018-09-14, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c6f142003d6, moduleTitle=CLIN CANCER RES：Pembrolizumab治疗雌激素受体阳性/HER2阴性晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c6f142003d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980854, encodeId=17be19808540d, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=JAMA ONCOL：循环肿瘤细胞与雌激素受体阳性乳腺癌晚期复发之间的关系, objectType=article, longId=145416, objectId=3f7d1454161d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f7d1454161d, replyNumber=0, likeNumber=85, createdTime=2019-01-24, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f7d1454161d, moduleTitle=JAMA ONCOL：循环肿瘤细胞与雌激素受体阳性乳腺癌晚期复发之间的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f7d1454161d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980855, encodeId=69f4198085549, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=ANN ONCOL：Palbociclib治疗雌激素受体阳性HER2阴性转移性乳腺癌, objectType=article, longId=147428, objectId=fcbd14e42869, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcbd14e42869, replyNumber=0, likeNumber=93, createdTime=2019-05-19, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcbd14e42869, moduleTitle=ANN ONCOL：Palbociclib治疗雌激素受体阳性HER2阴性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcbd14e42869)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980849, encodeId=b77d198084990, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=CLIN CANCER RES：乳腺癌雄激素受体阳性程度对预测疾病预后至关重要, objectType=article, longId=139784, objectId=4c81139e84ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c81139e84ab, replyNumber=0, likeNumber=97, createdTime=2019-02-23, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c81139e84ab, moduleTitle=CLIN CANCER RES：乳腺癌雄激素受体阳性程度对预测疾病预后至关重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c81139e84ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980850, encodeId=160e198085036, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=JCO：Ribociclib联合Fulvestrant治疗激素受体阳性，HER2阴性晚期乳腺癌, objectType=article, longId=139914, objectId=615f139914f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=615f139914f4, replyNumber=0, likeNumber=84, createdTime=2019-05-15, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=615f139914f4, moduleTitle=JCO：Ribociclib联合Fulvestrant治疗激素受体阳性，HER2阴性晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=615f139914f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980841, encodeId=6cf31980841e1, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Radiology：雌激素受体阳性乳腺癌复发风险？定性放射基因学组来说道说道！, objectType=article, longId=115243, objectId=57fd11524321, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57fd11524321, replyNumber=0, likeNumber=73, createdTime=2017-10-09, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57fd11524321, moduleTitle=Radiology：雌激素受体阳性乳腺癌复发风险？定性放射基因学组来说道说道！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57fd11524321)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980845, encodeId=71a219808457c, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=王晓稼教授：雌雄之辨，恩杂鲁胺治疗激素受体阳性乳腺癌, objectType=article, longId=123019, objectId=3f8812301964, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f8812301964, replyNumber=0, likeNumber=94, createdTime=2018-08-17, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f8812301964, moduleTitle=王晓稼教授：雌雄之辨，恩杂鲁胺治疗激素受体阳性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f8812301964)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980848, encodeId=402019808480a, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=NPJ Breast Cancer：卵巢切除术显著影响绝经前雌激素受体阳性乳腺癌基因表达, objectType=article, longId=129988, objectId=874112998818, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=874112998818, replyNumber=0, likeNumber=76, createdTime=2018-10-23, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=874112998818, moduleTitle=NPJ Breast Cancer：卵巢切除术显著影响绝经前雌激素受体阳性乳腺癌基因表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=874112998818)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980840, encodeId=4dc9198084077, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Int J GynecolCancer：阿那曲唑治疗雌激素受体或孕激素受体阳性的铂类耐药的复发性卵巢癌患者的二期临床试验, objectType=article, longId=103156, objectId=d8d010315642, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8d010315642, replyNumber=0, likeNumber=91, createdTime=2018-02-13, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8d010315642, moduleTitle=Int J GynecolCancer：阿那曲唑治疗雌激素受体或孕激素受体阳性的铂类耐药的复发性卵巢癌患者的二期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8d010315642)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980847, encodeId=80b8198084e07, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Oncogenesis：伊马替尼或可靶向治疗某些雌激素受体阳性乳腺小叶浸润癌, objectType=article, longId=129984, objectId=0c2c129984d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c2c129984d3, replyNumber=0, likeNumber=97, createdTime=2018-09-29, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c2c129984d3, moduleTitle=Oncogenesis：伊马替尼或可靶向治疗某些雌激素受体阳性乳腺小叶浸润癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c2c129984d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

激素受体阳性

2020-05-29

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

让激素受体阳性乳腺癌患者的选择不再困难

2019-09-06

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

Lancet Oncol：帕博西尼联合内分泌疗法治疗激素受体阳性、HER-2阴性的转移性乳腺癌

2020-05-29

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

Lancet Oncol：Tucidinostat联合依西美坦治疗激素受体阳性晚期乳腺癌

2020-03-01

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

王涛教授：激素受体阳性晚期乳腺癌一线优先推荐CDK4/6抑制剂联合内分泌治疗

2019-05-25

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

2019 ESMO|内分泌治疗是激素受体阳性乳腺癌重要的治疗手段，Abemaciclib显著延长HR+/HER2-mBC患者PFS

2020-04-28

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

绝经前激素受体阳性乳腺癌内分泌治疗选择卵巢功能抑制治疗获益评估

2020-08-07

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

PLOS ONE：雄激素受体阳性的三阴乳腺癌：临床病理，预后和预测特征

2019-04-14

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

JAMA Oncol：激素受体阳性男性乳腺癌的辅助内分泌治疗应用现状及疗效观察

2019-05-11

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

2018 AIOM建议：绝经前激素受体阳性的早期乳腺癌患者辅助内分泌治疗

2019-04-14

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

J Natl Cancer Inst：塞来昔布联用阿司匹林是绝经后激素受体阳性乳腺癌患者的福音？

2019-08-19

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

CLIN CANCER RES：Pembrolizumab治疗雌激素受体阳性/HER2阴性晚期乳腺癌

2018-09-14

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

JAMA ONCOL：循环肿瘤细胞与雌激素受体阳性乳腺癌晚期复发之间的关系

2019-01-24

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

ANN ONCOL：Palbociclib治疗雌激素受体阳性HER2阴性转移性乳腺癌

2019-05-19

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

CLIN CANCER RES：乳腺癌雄激素受体阳性程度对预测疾病预后至关重要

2019-02-23

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

JCO：Ribociclib联合Fulvestrant治疗激素受体阳性，HER2阴性晚期乳腺癌

2019-05-15

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

Radiology：雌激素受体阳性乳腺癌复发风险？定性放射基因学组来说道说道！

2017-10-09

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

王晓稼教授：雌雄之辨，恩杂鲁胺治疗激素受体阳性乳腺癌

2018-08-17

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

NPJ Breast Cancer：卵巢切除术显著影响绝经前雌激素受体阳性乳腺癌基因表达

2018-10-23

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

Int J GynecolCancer：阿那曲唑治疗雌激素受体或孕激素受体阳性的铂类耐药的复发性卵巢癌患者的二期临床试验

2018-02-13

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

Oncogenesis：伊马替尼或可靶向治疗某些雌激素受体阳性乳腺小叶浸润癌

2018-09-29

科室
- - 订阅+
  - 更多科室
工具
服务